Prevalence of Occult Hepatitis B Virus Infection in Blood Donors with Negative ID-NAT in Switzerland.
Anti-HBc screening
Blood donors
HBV-ID-NAT
Occult hepatitis B virus infection
Journal
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
01
2022
accepted:
05
06
2022
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
20
1
2023
Statut:
epublish
Résumé
Screening of hepatitis B surface antigen (HBsAg) and individual-donation nucleic acid amplification testing (ID-NAT) of blood donors have become standard to detect hepatitis B virus (HBV) infection. However, there is still a residual risk of HBV transmission by blood components of donors suffering from occult HBV infection (OBI). Therefore, many countries implemented universal testing of anti-HBV core antigen (anti-HBc) antibodies in order to increase blood safety. In Switzerland, anti-HBc testing is not part of the routine blood donor-screening repertoire. Therefore, we sought to assess prevalence of donors with OBI in a Swiss blood donor collective. Blood donations were prospectively investigated for the presence of anti-HBc antibodies during two time periods (I: all donors, March 2017; II: first-time donors only, April 2017 until February 2018). Anti-HBc-positive findings were confirmed by an anti-HBc neutralization test. Discarded plasma samples of anti-HBc-confirmed positive donors were ultracentrifuged and subsequently retested by regular HBV-ID-NAT to search for traces of HBV. During time period I, 78 (1.6%) individuals out of 4,923 donors were confirmed anti-HBc-positive. Sixty-nine (88%) anti-HBc-positive samples were available and processed by ultracentrifugation followed by repeat HBV-ID-NAT. Four samples (5.8%) were found positive for HBV DNA. Sixty-five (94.2%) samples remained HBV NAT-negative upon ultracentrifugation. During time period II, 56 (0.9%) donor samples out of 6,509 exhibited anti-HBc-confirmed positive. Fifty-five (98%) samples could be reassessed by HBV-ID-NAT upon ultracentrifugation. Three (5.5%) samples contained HBV DNA and 52 (94.5%) samples remained HBV NAT-negative. Overall, we detected 7 viremic OBI carriers among 11,432 blood donors, which tested negative for HBV by standard HBV-ID-NAT and HBsAg screening. In contrast, OBI carriers showed positive anti-HBc findings which could be confirmed in 83.8% of the cases. Thus, OBI might be missed by the current HBV screening process of Swiss blood donors. We suggest to review current HBV screening algorithm. Extended donor screening by anti-HBc testing may unmask OBI carriers and contribute to blood safety for the recipient of blood products.
Identifiants
pubmed: 36654973
doi: 10.1159/000525480
pii: tmh-0049-0338
pmc: PMC9768291
doi:
Types de publication
Journal Article
Langues
eng
Pagination
338-345Informations de copyright
Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Transfusion. 2014 Aug;54(8):2084-91
pubmed: 24650170
J Clin Virol. 2011 Aug;51(4):283-4
pubmed: 21632284
Vox Sang. 2010 May;98(4):504-7
pubmed: 20070649
Transfus Clin Biol. 2017 Sep;24(3):189-195
pubmed: 28673499
Transfus Med. 2010 Aug 1;20(4):276-7
pubmed: 20149156
Gut. 2019 Feb;68(2):313-321
pubmed: 29959168
Vox Sang. 2019 Jul;114(5):443-450
pubmed: 31012114
Diagn Microbiol Infect Dis. 2020 Apr;96(4):114985
pubmed: 32008810
Transfusion. 2007 Oct;47(10):1809-15
pubmed: 17880605
Transfusion. 2015 Jun;55(6):1206-13
pubmed: 25494685
Transfus Med Hemother. 2020 Jun;47(3):272-274
pubmed: 32595432
Transfusion. 2017 Mar;57(3pt2):841-849
pubmed: 28244600
Swiss Med Wkly. 2017 Mar 21;147:w14409
pubmed: 28322417
Transfusion. 2007 Jul;47(7):1197-205
pubmed: 17581154
Transfusion. 2021 Jul;61(7):2116-2124
pubmed: 33899233
Transfus Clin Biol. 2019 Nov;26(4):257-262
pubmed: 31153786
Transfusion. 2021 Aug;61(8):2402-2413
pubmed: 34114670
Transfusion. 2016 Mar;56(3):691-8
pubmed: 26559665
Vox Sang. 2015 Feb;108(2):113-22
pubmed: 25234417
Transfus Med Hemother. 2011;38(1):19-31
pubmed: 21779203
Transfusion. 2013 Jul;53(7):1405-15
pubmed: 23362802
J Hepatol. 2008 Oct;49(4):652-7
pubmed: 18715666
Swiss Med Wkly. 2008 Mar 8;138(9-10):134-41
pubmed: 18330733
Transfusion. 2010 Dec;50(12):2695-706
pubmed: 20573074
Blood Transfus. 2013 Apr;11(2):281-8
pubmed: 23399361
Transfusion. 2008 May;48(5):1001-26
pubmed: 18454738
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Vox Sang. 2019 Jul;114(5):459-466
pubmed: 30968958
Transfus Med Hemother. 2019 Apr;46(2):104-110
pubmed: 31191196
Transfusion. 2021 Jul;61(7):2125-2136
pubmed: 33955570